PD-153035 free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 202174

CAS#: 153436-54-5 (free base)

Description: PD153035 is a ATP-competitive EGFR inhibitor with an IC50 and Ki of 25 and 6 pM. PD153035 effectively blocks the enhancement of mitogenesis, induction of early gene expression, and oncogenic transformation that occur in response to EGF receptor stimulation. With human fibroblasts and epidermoid carcinoma cells, PD153035 at nanomolar concentrations rapidly inhibits EGFR autophosphorylation. With breast and ovarian cancer cells, PD153035 not only blocks cell growth via inhibition of EGFR, but also upregulates the expression of the tumor suppressor retinoic acid receptor-beta 2 (RAR-beta2).

Chemical Structure

img
PD-153035 free base
CAS# 153436-54-5 (free base)
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 202174
Name: PD-153035 free base
CAS#: 153436-54-5 (free base)
Chemical Formula: C16H14BrN3O2
Exact Mass: 359.03
Molecular Weight: 360.211
Elemental Analysis: C, 53.35; H, 3.92; Br, 22.18; N, 11.67; O, 8.88

Price and Availability

Size Price Availability Quantity
100mg USD 450
200mg USD 750 2 Weeks
500mg USD 1450 2 Weeks
1g USD 2450 2 Weeks
2g USD 3850 2 Weeks
Bulk inquiry

Related CAS #: 153436-54-5 (free base)   183322-45-4 (HCl)   205195-07-9 (xHCl)   586347-97-9 (nitrate)    

Synonym: PD-153035; PD 153035; PD153035; SU-5271; SU 5271; SU5271; AG-1517; AG 1517; AG1517; NSC 669364; NSC-669364; NSC669364; WHIP 79.

IUPAC/Chemical Name: N-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine

InChi Key: LSPANGZZENHZNJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H14BrN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)

SMILES Code: COC1=CC2=NC=NC(NC3=CC=CC(Br)=C3)=C2C=C1OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not soluble in water.

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# 183322-45-4 (PD153035 HCl) 153436-54-5 (PD153035 free base)    

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: PD153035 (SU-5271; AG1517; ZM 252868) is a potent EGFR inhibitor with Ki and IC50 of 6 and 25 pM.
In vitro activity: A small molecule called PD 153035 inhibited the epidermal growth factor (EGF) receptor tyrosine kinase with a 5-pM inhibition constant. The inhibitor was specific for the EGF receptor tyrosine kinase and inhibited other purified tyrosine kinases only at micromolar or higher concentrations. PD 153035 rapidly suppressed autophosphorylation of the EGF receptor at low nanomolar concentrations in fibroblasts or in human epidermoid carcinoma cells and selectively blocked EGF-mediated cellular processes including mitogenesis, early gene expression, and oncogenic transformation. Reference: Science. 1994 Aug 19;265(5175):1093-5. https://pubmed.ncbi.nlm.nih.gov/8066447/
In vivo activity: This study investigated whether inhibiting EGFR using the EGFR tyrosine kinase inhibitor (TKI) PD153035 improves NAFLD. These results demonstrate that EGFR was activated in liver tissues from high fat diet (HFD)-induced NAFLD mice. Inhibiting EGFR using PD153035 significantly reduced phosphatidylinositol-3-kinase/protein kinase B signaling and sterol responsive elementary binding protein 1 and 2 expression, which prevented HFD-induced hepatic steatosis and hypercholesterolemia by reducing de novo lipogenesis and cholesterol synthesis and enhancing fatty acid oxidation. Reference: PLoS One. 2019 Feb 8;14(2):e0210828. https://pubmed.ncbi.nlm.nih.gov/30735525/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMF 0.3 0.83
DMSO 13.8 38.25
DMSO:PBS (pH 7.2) (1:8) 0.1 0.31
Ethanol 0.6 1.54

Preparing Stock Solutions

The following data is based on the product molecular weight 360.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3(11):2099-106. PMID: 9815602. 2. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265(5175):1093-5. doi: 10.1126/science.8066447. PMID: 8066447. 3. Choung S, Kim JM, Joung KH, Lee ES, Kim HJ, Ku BJ. Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice. PLoS One. 2019 Feb 8;14(2):e0210828. doi: 10.1371/journal.pone.0210828. PMID: 30735525; PMCID: PMC6368280. 4. Kenessey I, Kramer Z, István L, Cserepes MT, Garay T, Hegedűs B, Dobos J, Tímár J, Tóvári J. Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model. Melanoma Res. 2018 Dec;28(6):536-546. doi: 10.1097/CMR.0000000000000488. PMID: 30124539.
In vitro protocol: 1. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov;3(11):2099-106. PMID: 9815602. 2. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 1994 Aug 19;265(5175):1093-5. doi: 10.1126/science.8066447. PMID: 8066447.
In vivo protocol: 1. Choung S, Kim JM, Joung KH, Lee ES, Kim HJ, Ku BJ. Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice. PLoS One. 2019 Feb 8;14(2):e0210828. doi: 10.1371/journal.pone.0210828. PMID: 30735525; PMCID: PMC6368280. 2. Kenessey I, Kramer Z, István L, Cserepes MT, Garay T, Hegedűs B, Dobos J, Tímár J, Tóvári J. Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model. Melanoma Res. 2018 Dec;28(6):536-546. doi: 10.1097/CMR.0000000000000488. PMID: 30124539.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message

Sent On: Tue Apr 14 16:45:05 2020

20 selected items


PubMed Results
Items 1-20 of 20 (Display the 20 citations in PubMed)

1: Zhang GN, Zhang YK, Wang YJ, Gupta P, Ashby CR Jr, Alqahtani S, Deng T, Bates SE, Kaddoumi A, Wurpel JND, Lei YX, Chen ZS. Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non- small cell lung cancer: In vitro and in vivo. Cancer Lett. 2018 Jun 28;424:19-29. doi: 10.1016/j.canlet.2018.02.040. Epub 2018 Mar 5. PMID: 29518481.


2: Prada PO, Ropelle ER, Mourão RH, de Souza CT, Pauli JR, Cintra DE, Schenka A, Rocco SA, Rittner R, Franchini KG, Vassallo J, Velloso LA, Carvalheira JB, Saad MJA. Statement of Retraction. EGFR Tyrosine Kinase Inhibitor (PD153035) Improves Glucose Tolerance and Insulin Action in High-Fat Diet-Fed Mice. Diabetes 2009;58:2910-2919. DOI: 10.2337/db08-0506. PMID: 19696185. Diabetes. 2017 Jul;66(7):2059. doi: 10.2337/db17-rt07a. Epub 2017 Apr 27. PMID: 28450418; PMCID: PMC5482084.


3: Prada PO, Ropelle ER, Mourão RH, de Souza CT, Pauli JR, Cintra DE, Schenka A, Rocco SA, Rittner R, Franchini KG, Vassallo J, Velloso LA, Carvalheira JB, Saad MJ. Expression of Concern. EGFR Tyrosine Kinase Inhibitor (PD153035) Improves Glucose Tolerance and Insulin Action in High-Fat Diet-Fed Mice. Diabetes 2009;58:2910-2919. DOI: 10.2337/db08-0506. PMID: 19696185. Diabetes. 2017 Apr;66(4):1098. doi: 10.2337/db17-ec04a. Epub 2017 Feb 10. PMID: 28188141; PMCID: PMC6973588.


4: Dai D, Li XF, Wang J, Liu JJ, Zhu YJ, Zhang Y, Wang Q, Xu WG. Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients. Int J Cancer. 2016 Feb 15;138(4):1003-12. doi: 10.1002/ijc.29832. Epub 2015 Sep 22. PMID: 26334931.


5: Leon Carrion S, Sutter CH, Sutter TR. Combined treatment with sodium butyrate and PD153035 enhances keratinocyte differentiation. Exp Dermatol. 2014 Mar;23(3):211-4. doi: 10.1111/exd.12333. PMID: 24451036; PMCID: PMC4046644.


6: Sun J, Cai L, Zhang K, Zhang A, Pu P, Yang W, Gao S. A pilot study on EGFR- targeted molecular imaging of PET/CT With 11C-PD153035 in human gliomas. Clin Nucl Med. 2014 Jan;39(1):e20-6. doi: 10.1097/RLU.0b013e3182a23b73. PMID: 24335566.


7: Samén E, Arnberg F, Lu L, Olofsson MH, Tegnebratt T, Thorell JO, Holmin S, Stone-Elander S. Metabolism of epidermal growth factor receptor targeting probe [11C]PD153035: impact on biodistribution and tumor uptake in rats. J Nucl Med. 2013 Oct;54(10):1804-11. doi: 10.2967/jnumed.113.120493. Epub 2013 Sep 3. PMID: 24003078.


8: Meng X, Loo BW Jr, Ma L, Murphy JD, Sun X, Yu J. Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study. J Nucl Med. 2011 Oct;52(10):1573-9. doi: 10.2967/jnumed.111.092874. Epub 2011 Sep 8. PMID: 21903741.


9: Cheng CM, Lee YJ, Wang WT, Hsu CT, Tsai JS, Wu CM, Ou KL, Yang TS. Determining the binding mode and binding affinity constant of tyrosine kinase inhibitor PD153035 to DNA using optical tweezers. Biochem Biophys Res Commun. 2011 Jan 7;404(1):297-301. doi: 10.1016/j.bbrc.2010.11.110. Epub 2010 Dec 2. PMID: 21130075.


10: Cavalheiro RA, Marin RM, Rocco SA, Cerqueira FM, da Silva CC, Rittner R, Kowaltowski AJ, Vercesi AE, Franchini KG, Castilho RF. Potent cardioprotective effect of the 4-anilinoquinazoline derivative PD153035: involvement of mitochondrial K(ATP) channel activation. PLoS One. 2010 May 17;5(5):e10666. doi: 10.1371/journal.pone.0010666. PMID: 20498724; PMCID: PMC2871796.


11: Prada PO, Ropelle ER, Mourão RH, de Souza CT, Pauli JR, Cintra DE, Schenka A, Rocco SA, Rittner R, Franchini KG, Vassallo J, Velloso LA, Carvalheira JB, Saad MJ. EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice. Diabetes. 2009 Dec;58(12):2910-9. doi: 10.2337/db08-0506. Epub 2009 Aug 20. Retraction in: Diabetes. 2017 Jul;66(7):2059. PMID: 19696185; PMCID: PMC2780887.


12: Liu N, Li M, Li X, Meng X, Yang G, Zhao S, Yang Y, Ma L, Fu Z, Yu J. PET- based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans. J Nucl Med. 2009 Feb;50(2):303-8. doi: 10.2967/jnumed.108.056556. Epub 2009 Jan 21. PMID: 19164239.


13: Grunt TW, Tomek K, Wagner R, Puckmair K, Zielinski CC. The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells. Differentiation. 2007 Nov;75(9):883-90. doi: 10.1111/j.1432-0436.2007.00199.x. Epub 2007 Jul 2. PMID: 17608728.


14: Wang H, Yu JM, Yang GR, Song XR, Sun XR, Zhao SQ, Wang XW, Zhao W. Further characterization of the epidermal growth factor receptor ligand 11C-PD153035. Chin Med J (Engl). 2007 Jun 5;120(11):960-4. PMID: 17624262.


15: Grunt TW, Tomek K, Wagner R, Puckmair K, Kainz B, Rünzler D, Gaiger A, Köhler G, Zielinski CC. Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways. J Cell Physiol. 2007 Jun;211(3):803-15. doi: 10.1002/jcp.20990. PMID: 17286282.


16: Jia C, Zhou Z, Liu R, Chen S, Xia R. EGF receptor clustering is induced by a 0.4 mT power frequency magnetic field and blocked by the EGF receptor tyrosine kinase inhibitor PD153035. Bioelectromagnetics. 2007 Apr;28(3):197-207. doi: 10.1002/bem.20293. PMID: 17019730.


17: Samén E, Thorell JO, Fredriksson A, Stone-Elander S. The tyrosine kinase inhibitor PD153035: implication of labeling position on radiometabolites formed in vitro. Nucl Med Biol. 2006 Nov;33(8):1005-11. doi: 10.1016/j.nucmedbio.2006.09.008. PMID: 17127174.


18: Cole GW Jr, Alleva AM, Reddy RM, Maxhimer JB, Zuo J, Schrump DS, Nguyen DM. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg. 2005 May;129(5):1010-7. doi: 10.1016/j.jtcvs.2004.10.040. PMID: 15867774.


19: Rocco SA, Velho JA, Marin RM, de Arruda Rolim Filho L, Vercesi AE, Rittner R, Franchini KG. High performance liquid chromatography analysis of a 4-anilinoquinazoline derivative (PD153035), a specific inhibitor of the epidermal growth factor receptor tyrosine kinase, in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Mar 25;817(2):297-302. doi: 10.1016/j.jchromb.2004.12.021. PMID: 15686998.


20: He XY, Huang JA, Xie W, Jiang LY, Wang YD. [Role of PD153035 in the induction of apoptosis of XG-1 myeloma cell line]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004 Oct;26(5):492-5. Chinese. PMID: 15562758.